Evogene Ltd. (NASDAQ: EVGN) reported a second-quarter loss of $0.13 per share, exceeding expectations and narrowing from a year-earlier loss of $0.28 per share. Revenue totaled $350,000, up from $325,000 in the same period last year and ahead of the $325,000 consensus estimate.
The company’s net loss for the quarter was $2.8 million, compared with a loss of $3.7 million in the prior-year period. Operating expenses declined 12% year-over-year to $3.2 million, driven by lower research and development spending.
Evogene’s stock closed at $0.56 on Monday, bringing its three-month decline to 19.24% and its 12-month drop to 55.91%. The shares have underperformed broader biotech benchmarks amid a challenging funding environment for early-stage life sciences companies.
Analysts at Bank of America maintained a neutral rating on the stock following the results, citing ongoing execution risks despite the top-line beat. Evogene’s Financial Health score, as tracked by InvestingPro, was classified as "fair performance," reflecting mixed metrics across liquidity and profitability indicators.
The company has faced both upward and downward EPS revisions over the past 90 days, with consensus estimates for the current fiscal year pointing to a loss of $0.55 per share. Evogene did not provide updated guidance in its earnings release.
